Last reviewed · How we verify
dolutegravir/abacavir/lamivudine
This combination inhibits HIV reverse transcriptase and integrase to block viral replication at multiple steps.
This combination inhibits HIV reverse transcriptase and integrase to block viral replication at multiple steps. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).
At a glance
| Generic name | dolutegravir/abacavir/lamivudine |
|---|---|
| Also known as | Triumeq |
| Sponsor | University College Dublin |
| Drug class | Antiretroviral combination (INSTI + NRTIs) |
| Target | HIV integrase, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Dolutegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV from integrating its genetic material into the host cell genome. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block the reverse transcriptase enzyme, preventing conversion of viral RNA to DNA. Together, these three agents provide complementary antiretroviral activity against HIV-1.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in adolescents and children (weight-based dosing)
Common side effects
- Hypersensitivity reaction (abacavir-related)
- Nausea
- Diarrhea
- Headache
- Insomnia
- Fatigue
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study of GS-3242 in Participants With HIV-1; Substudy-05 (PHASE1)
- Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 (PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study of GS-1219 in Participants With HIV-1 (PHASE1)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dolutegravir/abacavir/lamivudine CI brief — competitive landscape report
- dolutegravir/abacavir/lamivudine updates RSS · CI watch RSS
- University College Dublin portfolio CI